[Skip to Content]
[Skip to Content Landing]
April 1987

Anthralin Minute Entire Skin Treatment: A Follow-up and Comparison With Methoxsalen Plus Ultraviolet Light

Arch Dermatol. 1987;123(4):428-429. doi:10.1001/archderm.1987.01660280028012

To the Editor.—  Anthralin minute entire skin treatment (AMEST) has been developed as a new antipsoriatic regimen1 to improve the efficacy, practicability, and cosmetic results of anthralin short-contact therapy. Using the dosimetry parameters of AMEST,1 this treatment has proved a successful and safe outpatient therapy for psoriasis. In our original report, published recently,1 43 patients were treated with AMEST and clearing was achieved in 77%, with excellent cosmetic results in most of the patients. Due to the short observation period, however, we were not able to evaluate the duration of the remission phase and the response to a second therapeutic course. In the present study, 131 patients (82 women and 49 men; age, 48 ± 16 years; duration of psoriasis, 16 ± 13 years; and skin pigmentation: type I/II, 79 patients; type III/IV, 52 patients) were allocated to AMEST therapy, and the therapeutic results yielded by AMEST